|
Mace L. Rothenberg, MD, is a professor of medicine at the Vanderbilt University Medical Center and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center.
A 1982 graduate of New York University School of Medicine, Dr. Rothenberg trained as an intern and resident in internal medicine at Vanderbilt University from 1982 to 1985. He obtained his medical oncology training at the National Cancer Institute (NCI) from 1985 to 1988 and served as special assistant to the director, division of cancer treatment, from 1988 to 1991. In 1991, he was appointed assistant professor, then associate professor, in the department of medicine, division of medical oncology at the University of Texas Health Science Center in San Antonio, and executive officer of the Southwest Oncology Group. In 1998, Dr. Rothenberg returned to Vanderbilt, where he is currently a professor of medicine, the Ingram Professor of Cancer Research, director of Phase I drug development, co-leader of the experimental therapeutics orogram, and director of clinical and translational research for the Vanderbilt SPORE in gastrointestinal cancer.
Dr. Rothenberg is active in clinical-translational research (supported by U01 and P50 grants from the NCI) as well as teaching and mentoring early-career investigators (supported by a K24 grant from the NCI). He has served as an ad hoc reviewer on several NIH study sections. He has published more than 100 articles and book chapters, primarily in the areas of early-stage drug development, gastrointestinal malignancies and ovarian cancer. He serves on the editorial boards of several leading medical journals, including the Journal of Clinical Oncology, Investigational New Drugs, Cancer Chemotherapy and Pharmacology and Clinical Colorectal Cancer. Dr. Rothenberg’s research focuses on the evaluation of new drugs in humans from clinical, pharmacologic, biologic and genetic perspectives. His work was critical to the development and eventual US Food and Drug Administration approval of irinotecan (CPT-11, Camptosar®) in 1996, oxaliplatin (Eloxatin®) in 2002 for colorectal cancer and gemcitabine (Gemzar®) in 1996 for pancreatic cancer. | 